UK pharmaceutical giant AstraZeneca was downgraded to underweight from neutral on Monday at JP Morgan, which said the company has a strong track record of beating estimates, but this will get tougher in coming quarters as it has to digest generic competition of high-margin products.
50724
AstraZeneca downgraded to underweight at JP Morgan
58195
Drug stocks flee into negative territory
59944
Major averages moving back to the downside
43647
Marginally underweight on financials:
24216
Sensex slips further;
48352
JP Morgan downgrades Bank of India to 'Underweight'
40368
Silver touched an intraday low of $9.15
72746
Drug originally intended to lower
97157
Pharmaceutical firms lead FTSE 100 higher
48605
Semtech falls on analyst downgrade
62571
Jp Morgan upgrades Indian stocks to overweight
97837
DR Horton reports narrower loss
141919
FTSE 100 opens lower
128027
Jpmorgan upgrades Indian equities to 'overweight'
95584
Wockhardt gains on launching generic of Wellbutrin SR in US
71570
Citigroup downgrades Turkish assets to ``neutral''
112289
Drug stocks retract;